NasdaqGS:EWTX
NasdaqGS:EWTXPharmaceuticals

Will Edgewise Therapeutics’ (EWTX) Rising Losses Reshape Its Long-Term Investment Strategy?

Edgewise Therapeutics, Inc. reported its second quarter and six-month earnings for the period ended June 30, 2025, disclosing a net loss of US$36.12 million for the quarter and US$76.91 million for the half-year, both increases from the same periods last year. Although the company's per-share loss for the quarter remained flat at US$0.34, overall losses grew year-over-year reflecting rising expenses or investment activity. Given the rise in net loss while per-share loss stayed unchanged,...